Publications

Publications published since 2000 or in press from OUS - Department of Gynaecological Oncology

313 publications found

Publications in press

1. Bock AJ, Nymoen DA, Brenne K, Kærn J, Davidson B
   SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
   Hum Pathol (in press)
   PubMed 21855113
2. Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B
   Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
   Hum Pathol (in press)
   PubMed 21855111
3. Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B
   Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
   Virchows Arch (in press)
   PubMed 22249560
4. Dahl AA, Gudbergsson SB, Dørum A, Fosså SD, Liavaag AH, Sørebø O
   "The impact of cancer scale" version 1: psychometric testing of the Norwegian translation in a heterogeneous sample of cancer survivors
   Qual Life Res (in press)
   PubMed 22045155
5. Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Tropé CG
   Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
   Acta Obstet Gynecol Scand (in press)
   PubMed 22050605
6. Elstrand MB, Stavnes HT, Tropé CG, Davidson B
   Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
   Hum Pathol (in press)
   PubMed 21864883
7. Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA
   Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
   Cancer Chemother Pharmacol (in press)
   PubMed 22302409
8. Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg BA
   Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium
   Ann Oncol (in press)
   PubMed 21965471

Publications 2012

1. Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2012)
   Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance
   Int J Radiat Oncol Biol Phys, 82 (3), e485-92
   PubMed 22014954
2. Bock AJ, Dong HP, Tropé CG, Staff AC, Risberg B, Davidson B (2012)
   Nucleoside transporters are widely expressed in ovarian carcinoma effusions
   Cancer Chemother Pharmacol, 69 (2), 467-75
   PubMed 21822668
3. Kildal W, Micci F, Risberg B, Abeler VM, Kristensen GB, Heim S, Danielsen HE (2012)
   Genomic imbalances in endometrial adenocarcinomas - Comparison of DNA ploidy, karyotyping and comparative genomic hybridization
   Mol Oncol, 6 (1), 98-107
   PubMed 22062770
4. Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P (2012)
   A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection
   Ann Surg Oncol, 19 (2), 597-604
   PubMed 21732142

Publications 2011

1. Andersen EK, Kristensen GB, Lyng H, Malinen E (2011)
   Pharmacokinetic analysis and k-means clustering of DCEMR images for radiotherapy outcome prediction of advanced cervical cancers
   Acta Oncol, 50 (6), 859-65
   PubMed 21767185
2. Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B (2011)
   Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
   Tumour Biol, 32 (3), 589-96
   PubMed 21350924
3. Davidson B, Holth A, Moripen L, Trope' CG, Shih IeM (2011)
   Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
   Hum Pathol, 42 (7), 991-7
   PubMed 21315424
4. Dong HP, Ree Rosnes AK, Bock AJ, Holth A, Flørenes VA, Trope' CG, Risberg B, Davidson B (2011)
   Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
   Cytopathology, 22 (6), 373-82
   PubMed 22032542
5. Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM (2011)
   Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions
   Mol Pharm, 8 (6), 2080-8
   PubMed 21761824
6. Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP, Piek JM, Manchanda R, Grimm C, Dallaku K, Babloyan S, Moisei A, Van Gorp T, Cadron I, Markov P, Micevska A, Halaska M, Steffensen KD, Gristsenko L, Nissi R, Lambaudie E, Tsitsishvili Z, Haidopoulos D, Tsolakidis D, Novak Z et al. (2011)
   Gynecologic oncology training systems in europe: a report from the European network of young gynaecological oncologists
   Int J Gynecol Cancer, 21 (8), 1500-6
   PubMed 21720256
7. Halle C, Lando M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
   Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer
   Radiother Oncol, 101 (1), 152-7
   PubMed 21680035
8. Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
   Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer
   Clin Cancer Res, 17 (16), 5501-12
   PubMed 21737508
9. Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J (2011)
   Class III ?-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
   Hum Pathol, 42 (7), 1019-26
   PubMed 21315408
10. Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS et al. (2011)
    The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
    Cancer Cell, 19 (2), 273-82
    PubMed 21316605
11. Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E, Gynecologic Cancer Intergroup (2011)
    Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
    Ann Oncol, 22 (11), 2417-23
    PubMed 21402619
12. Oksefjell H, Sandstad B, Tropé C (2011)
    The role of surgery in the second relapse of epithelial ovarian cancer. Selection criteria, morbidity and survival outcome
    Eur J Gynaecol Oncol, 32 (4), 369-76
    PubMed 21941955
13. Paulsen T, Kærn J, Tropé C (2011)
    Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
    Gynecol Oncol, 122 (1), 83-8
    PubMed 21435701
14. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK et al. (2011)
    A phase 3 trial of bevacizumab in ovarian cancer
    N Engl J Med, 365 (26), 2484-96
    PubMed 22204725
15. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J, Gynecological Cancer Intergroup (2011)
    Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
    Int J Gynecol Cancer, 21 (2), 419-23
    PubMed 21270624
16. Sert MB, Abeler V (2011)
    Robot-assisted laparoscopic radical hysterectomy: comparison with total laparoscopic hysterectomy and abdominal radical hysterectomy; one surgeon's experience at the Norwegian Radium Hospital
    Gynecol Oncol, 121 (3), 600-4
    PubMed 21353294
17. Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC, Gynecologic Cancer InterGroup (2011)
    First-line therapy in ovarian cancer trials
    Int J Gynecol Cancer, 21 (4), 756-62
    PubMed 21543937
18. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R (2011)
    miRNA profiling along tumour progression in ovarian carcinoma
    J Cell Mol Med, 15 (7), 1593-602
    PubMed 20716115
19. Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A (2011)
    Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer
    Eur J Cancer, 47 Suppl 3, S88-92
    PubMed 21944035
20. Vergote I, Tropé CG, Amant F, Ehlen T, Reed NS, Casado A (2011)
    Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer
    J Clin Oncol, 29 (31), 4076-8
    PubMed 21931032
21. Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, Reed NS, Verheijen RH, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I (2011)
    Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial
    Eur J Cancer, 47 (1), 57-64
    PubMed 20850296
22. Vistad I, Cvancarova M, Kristensen GB, Fosså SD (2011)
    A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer
    J Cancer Surviv, 5 (2), 208-16
    PubMed 21259075
23. Wang Z, Nesland JM, Suo Z, Trope CG, Holm R (2011)
    The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3? and ? are independent prognostic factors for these tumors
    PLoS One, 6 (9), e24843
    PubMed 21935479
24. Yuan Y, Leszczynska M, Konstantinovsky S, Tropé CG, Reich R, Davidson B (2011)
    Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors
    Diagn Cytopathol, 39 (8), 562-6
    PubMed 20730893
25. Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS (2011)
    Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
    Br J Cancer, 105 (7), 890-6
    PubMed 21878937

Publications 2010

1. Bock AJ, Stavnes HT, Kempf T, Tropè CG, Berner A, Davidson B, Staff AC (2010)
   Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
   Int J Gynecol Cancer, 20 (9), 1448-55
   PubMed 21336029
2. Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B (2010)
   Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
   Hum Pathol, 41 (6), 794-804
   PubMed 20153512
3. Davidson B, Reich R, Trope CG, Wang TL, Shih IeM (2010)
   New determinates of disease progression and outcome in metastatic ovarian carcinoma
   Histol Histopathol, 25 (12), 1591-609
   PubMed 20886439
4. du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J (2010)
   Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
   J Clin Oncol, 28 (27), 4162-9
   PubMed 20733132
5. Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, Staff AC, Sauer T, Gautvik KM (2010)
   POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas
   PLoS One, 5 (11), e13837
   PubMed 21079801
6. Elloul S, Vaksman O, Stavnes HT, Trope CG, Davidson B, Reich R (2010)
   Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions
   Clin Exp Metastasis, 27 (3), 161-72
   PubMed 20213325
7. Hellebust TP, Kristensen GB, Olsen DR (2010)
   Late effects after radiotherapy for locally advanced cervical cancer: comparison of two brachytherapy schedules and effect of dose delivered weekly
   Int J Radiat Oncol Biol Phys, 76 (3), 713-8
   PubMed 19427739
8. Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G (2010)
   Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies
   Eur J Cancer, 46 (13), 2422-31
   PubMed 20619634
9. Hovland S, Arbyn M, Lie AK, Ryd W, Borge B, Berle EJ, Skomedal H, Kadima TM, Kyembwa L, Billay EM, Mukwege D, Chirimwami RB, Mvula TM, Snijders PJ, Meijer CJ, Karlsen F (2010)
   A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo
   Br J Cancer, 102 (6), 957-65
   PubMed 20197765
10. Khouja MH, Baekelandt M, Sarab A, Nesland JM, Holm R (2010)
    Limitations of tissue microarrays compared with whole tissue sections in survival analysis
    Oncol. Lett., 1 (5), 827-831
11. Micci F, Haugom L, Ahlquist T, Andersen HK, Abeler VM, Davidson B, Trope CG, Lothe RA, Heim S (2010)
    Genomic aberrations in borderline ovarian tumors
    J Transl Med, 8, 21
    PubMed 20184781
12. Micci F, Skotheim RI, Haugom L, Weimer J, Eibak AM, Abeler VM, Trope CG, Arnold N, Lothe RA, Heim S (2010)
    Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes
    Genes Chromosomes Cancer, 49 (11), 1046-53
    PubMed 20725991
13. Michelsen TM, Tonstad S, Pripp AH, Tropé CG, Dørum A (2010)
    Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer
    Int J Gynecol Cancer, 20 (2), 233-9
    PubMed 20169665
14. Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL (2010)
    Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin
    Am J Pathol, 177 (3), 1087-94
    PubMed 20671266
15. Pradhan M, Abeler VM, Davidson B, Kildal W, Nybøen A, Tropé CG, Risberg B, Danielsen HE (2010)
    DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens
    Int J Gynecol Pathol, 29 (6), 572-8
    PubMed 20881853
16. Pradhan M, Risberg BA, Tropé CG, van de Rijn M, Gilks CB, Lee CH (2010)
    Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
    BMC Cancer, 10, 493
    PubMed 20843305
17. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010)
    Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
    J Clin Oncol, 28 (20), 3323-9
    PubMed 20498395
18. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM, MRC OV05, EORTC 55955 investigators (2010)
    Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
    Lancet, 376 (9747), 1155-63
    PubMed 20888993
19. Sert B (2010)
    Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes
    Int J Med Robot, 6 (2), 132-5
    PubMed 20049750
20. Sert MB (2010)
    Comparison between robot-assisted laparoscopic radical hysterectomy (RRH) and abdominal radical hysterectomy (ARH): a case control study from EIO/Milan
    Gynecol Oncol, 117 (2), 389; author reply 389-90
    PubMed 20153028
21. Tropé CG (2010)
    Management of cervical carcinoma stage IV: comment.
    CME Journal of Gynecologic Oncology, 15 (1), 69-71
    PublikaID 105
22. Tropé CG, Kristensen GB (2010)
    The treatment of recurrent cervical cancer
    CME Journal of Gynecologic Oncology, 15 (1), 72-90
    PublikaID 106
23. Tropé CG, Kristensen GB (2010)
    Surgery in treatment of recurrent cervical cancer
    CME Journal of Gynecologic Oncology, 15 (1), 33-39
    PublikaID 104
24. Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee AG, du Bois A, European Network of Gynaecological Oncological Trial Groups (2010)
    European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies
    Int J Gynecol Cancer, 20 (3), 476-8
    PubMed 20375816
25. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group (2010)
    Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
    N Engl J Med, 363 (10), 943-53
    PubMed 20818904
26. Wang Z, Trope CG, Flørenes VA, Suo Z, Nesland JM, Holm R (2010)
    Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
    BMC Cancer, 10, 233
    PubMed 20500813

Publications 2009

1. Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB (2009)
   Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients
   Histopathology, 54 (3), 355-64
   PubMed 19236512
2. Baekelandt MM, Castiglione M, ESMO Guidelines Working Group (2009)
   Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
   Ann Oncol, 20 Suppl 4, 29-31
   PubMed 19454455
3. Davidson B, Hadar R, Stavnes HT, Trope' CG, Reich R (2009)
   Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival
   Hum Pathol, 40 (5), 705-13
   PubMed 19157507
4. Dong HP, Holth A, Kleinberg L, Ruud MG, Elstrand MB, Tropé CG, Davidson B, Risberg B (2009)
   Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters
   Am J Clin Pathol, 132 (5), 756-62
   PubMed 19846818
5. Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B (2009)
   Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma
   Int J Gynecol Pathol, 28 (3), 211-21
   PubMed 19620938
6. Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P (2009)
   Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers
   J Med Genet, 46 (9), 593-7
   PubMed 18413372
7. Holm R, Ali T, Svendsrud DH, Nesland JM, Kristensen GB, Lyng H (2009)
   Expression of 14-3-3sigma in cervical squamous cell carcinomas: relationship with clinical outcome
   Oncol Rep, 22 (1), 11-5
   PubMed 19513498
8. Kildal W, Pradhan M, Abeler VM, Kristensen GB, Danielsen HE (2009)
   Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters
   Eur J Cancer, 45 (13), 2412-7
   PubMed 19622417
9. Knopp S, Tropè C, Nesland JM, Holm R (2009)
   A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice
   J Clin Pathol, 62 (3), 212-8
   PubMed 19251952
10. Lando M, Holden M, Bergersen LC, Svendsrud DH, Stokke T, Sundfør K, Glad IK, Kristensen GB, Lyng H (2009)
    Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer
    PLoS Genet, 5 (11), e1000719
    PubMed 19911042
11. Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2009)
    Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors
    BMC Cancer, 9, 2
    PubMed 19121203
12. Liavaag AH, Tonstad S, Pripp AH, Tropé C, Dørum A (2009)
    Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors: a controlled observational study
    Int J Gynecol Cancer, 19 (4), 634-40
    PubMed 19509562
13. Micci F, Haugom L, Ahlquist T, Abeler VM, Trope CG, Lothe RA, Heim S (2009)
    Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution
    J Oncol, 2010, 646340
    PubMed 19759843
14. Michelsen TM, Dørum A, Dahl AA (2009)
    A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer
    Gynecol Oncol, 113 (1), 128-33
    PubMed 19178933
15. Michelsen TM, Dørum A, Tropé CG, Fosså SD, Dahl AA (2009)
    Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer
    Int J Gynecol Cancer, 19 (6), 1029-36
    PubMed 19820364
16. Michelsen TM, Pripp AH, Tonstad S, Tropé CG, Dørum A (2009)
    Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study
    Eur J Cancer, 45 (1), 82-9
    PubMed 19008092
17. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB (2009)
    Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis
    PLoS One, 4 (5), e5583
    PubMed 19440550
18. Oksefjell H, Sandstad B, Tropé C (2009)
    The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer
    Ann Oncol, 20 (2), 286-93
    PubMed 18725390
19. Pradhan M, Davidson B, Tropé CG, Danielsen HE, Abeler VM, Risberg B (2009)
    Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications
    Virchows Arch, 454 (6), 677-83
    PubMed 19421773
20. Sert MB (2009)
    Robot assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy with short and long term morbidity
    Gynecol Oncol, 115 (1), 164-5; author reply 165-6
    PubMed 19539356
21. Sert MB, Eraker R (2009)
    Robot-assisted laparoscopic surgery in gynaecological oncology; initial experience at Oslo Radium Hospital and 16 months follow-up
    Int J Med Robot, 5 (4), 410-4
    PubMed 19569081
22. Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J (2009)
    Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
    Eur J Gynaecol Oncol, 30 (5), 471-82
    PubMed 19899396
23. Tropé C, Iversen OE (2009)
    [From wonder to alarm--the Tidsskriftet, the Nobel Prize and the HPV vaccine]
    Tidsskr Nor Laegeforen, 129 (7), 651; author reply 651
    PubMed 19337352
24. Vistad I, Kristensen GB, Fosså SD, Dahl AA, Mørkrid L (2009)
    Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy
    Int J Radiat Oncol Biol Phys, 73 (4), 1141-7
    PubMed 18760883
25. Yuan Y, Nymoen DA, Dong HP, Bjørang O, Shih IeM, Low PS, Trope' CG, Davidson B (2009)
    Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions
    Hum Pathol, 40 (10), 1453-60
    PubMed 19454358

Publications 2008

1. Baekelandt MM, Castiglione M, ESMO Guidelines Working Group (2008)
   Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
   Ann Oncol, 19 Suppl 2, ii19-20
   PubMed 18456753
2. Box I, Marrannes J, De Peuter B, Baekelandt M (2008)
   Large mammographic opacity due to hamartoma
   JBR-BTR, 91 (4), 177
   PubMed 18817100
3. Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B (2008)
   Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
   Cancer, 112 (1), 84-93
   PubMed 17985388
4. Dørum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA (2008)
   Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2)
   Gynecol Oncol, 109 (3), 377-83
   PubMed 18407340
5. Holm R, de Putte GV, Suo Z, Lie AK, Kristensen GB (2008)
   Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis
   Int J Med Sci, 5 (3), 121-6
   PubMed 18566674
6. Holm R, Knopp S, Kumar R, Lee J, Nesland JM, Tropè C, Callen DF (2008)
   Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis
   J Clin Pathol, 61 (1), 59-63
   PubMed 17468294
7. Holm R, Kraus I, Skomedal H, Langerød A, Kristensen GB, Lyng H (2008)
   Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma
   Open Virol J, 2, 74-81
   PubMed 19440467
8. Kleinberg L, Holth A, Trope CG, Reich R, Davidson B (2008)
   Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
   Hum Pathol, 39 (5), 747-57
   PubMed 18439941
9. Kleinberg L, Pradhan M, Tropé CG, Nesland JM, Davidson B, Risberg B (2008)
   Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors
   Diagn Cytopathol, 36 (9), 637-44
   PubMed 18677760
10. Knopp S, Nesland JM, Tropé C (2008)
    SLNB and the importance of micrometastases in vulvar squamous cell carcinoma
    Surg Oncol, 17 (3), 219-25
    PubMed 18556194
11. Lhommé C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ, Dugan MH (2008)
    Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer
    J Clin Oncol, 26 (16), 2674-82
    PubMed 18509179
12. Liavaag AH, Dørum A, Bjøro T, Oksefjell H, Fosså SD, Tropé C, Dahl AA (2008)
    A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach
    Gynecol Oncol, 108 (2), 348-54
    PubMed 17996925
13. Lieng M, Qvigstad E, Dahl GF, Istre O (2008)
    Flow differences between endometrial polyps and cancer: a prospective study using intravenous contrast-enhanced transvaginal color flow Doppler and three-dimensional power Doppler ultrasound
    Ultrasound Obstet Gynecol, 32 (7), 935-40
    PubMed 19035544
14. Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
    GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
    Genome Biol, 9 (5), R86
    PubMed 18500990
15. Micci F, Haugom L, Abeler VM, Tropé CG, Danielsen HE, Heim S (2008)
    Consistent numerical chromosome aberrations in thecofibromas of the ovary
    Virchows Arch, 452 (3), 269-76
    PubMed 18188592
16. Oksefjell H, Sandstad B, Tropé C (2008)
    Is the watch and wait approach adequate after comprehensive surgical staging in invasive stage I epithelial ovarian cancer? The Norwegian Radium Hospital experience
    Eur J Gynaecol Oncol, 29 (6), 583-9
    PubMed 19115683
17. Vistad I, Cvancarova M, Fosså SD, Kristensen GB (2008)
    Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?
    Int J Radiat Oncol Biol Phys, 71 (5), 1335-42
    PubMed 18355976
18. Wang Z, Tropè CG, Suo Z, Trøen G, Yang G, Nesland JM, Holm R (2008)
    The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas
    BMC Cancer, 8, 308
    PubMed 18950492
19. Ødegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, Staff AC (2008)
    Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary
    Am J Obstet Gynecol, 198 (4), 418.e1-7
    PubMed 18241816

Publications 2007

1. [No authors] (2007)
   An international perspective on surgical health care and education
   J Am Coll Surg, 204 (1), 148-57
   PubMed 17189123
2. Davidson B, Berner A, Trope' CG, Wang TL, Shih IeM (2007)
   Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions
   Hum Pathol, 38 (7), 1030-6
   PubMed 17391728
3. Davidson B, Shafat I, Risberg B, Ilan N, Trope' CG, Vlodavsky I, Reich R (2007)
   Heparanase expression correlates with poor survival in metastatic ovarian carcinoma
   Gynecol Oncol, 104 (2), 311-9
   PubMed 17030350
4. Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA (2007)
   Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
   Cancer, 110 (6), 1264-71
   PubMed 17647260
5. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA (2007)
   Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers
   Mol Cancer, 6, 12
   PubMed 17274819
6. Holm R, Knopp S, Suo Z, Tropè C, Nesland JM (2007)
   Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis
   J Clin Pathol, 60 (10), 1086-91
   PubMed 17158642
7. Khouja MH, Baekelandt M, Nesland JM, Holm R (2007)
   The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma
   Int J Gynecol Pathol, 26 (4), 418-25
   PubMed 17885492
8. Kleinberg L, Flørenes VA, Silins I, Haug K, Trope CG, Nesland JM, Davidson B (2007)
   Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
   Cancer, 109 (2), 228-38
   PubMed 17167759
9. Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2007)
   Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?
   J Clin Oncol, 25 (15), 2049-56
   PubMed 17513809
10. Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfør K, Kristensen GB, Gribbestad IS (2007)
    Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas
    BMC Cancer, 7, 11
    PubMed 17233882
11. Marth C, Walker JL, Barakat RR, Casado A, Gadducci A, Miller B, Odicino F, Pujade-Lauraine E, Sehouli J, Tropé C, Wenzel L, Zeimet AG (2007)
    Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer
    Cancer, 109 (4), 645-9
    PubMed 17238177
12. Oksefjell H, Sandstad B, Tropé C (2007)
    Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001
    Eur J Gynaecol Oncol, 28 (4), 256-62
    PubMed 17713088
13. Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM (2007)
    Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
    Eur J Gynaecol Oncol, 28 (5), 356-63
    PubMed 17966213
14. Sert B, Abeler V (2007)
    Robotic radical hysterectomy in early-stage cervical carcinoma patients, comparing results with total laparoscopic radical hysterectomy cases. The future is now?
    Int J Med Robot, 3 (3), 224-8
    PubMed 17924449
15. Trimble EL, Davis J, Disaia P, Fujiwara K, Gaffney D, Kristensen G, Ledermann J, Pfisterer J, Quinn M, Reed N, Schoenfeldt M, Thigpen JT, Gynecologic Cancer Intergroup (2007)
    Clinical trials in gynecological cancer
    Int J Gynecol Cancer, 17 (3), 547-56
    PubMed 17504371
16. Tropé C, Kaern J (2007)
    Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature
    J Clin Oncol, 25 (20), 2909-20
    PubMed 17617522
17. Vergote I, van der Zee AG, Kesic V, Sert B, Robova H, Rob L, Reed N, Luesley DM, Leblanc E, Hagen B, Gitsch G, du Bois A, di Vagno G, Colombo N, Beller U, Ayhan A, Jacobs I (2007)
    ESGO statement on cervical cancer vaccination
    Int J Gynecol Cancer, 17 (6), 1183-5
    PubMed 17997794
18. Vistad I, Fosså SD, Kristensen GB, Dahl AA (2007)
    Chronic fatigue and its correlates in long-term survivors of cervical cancer treated with radiotherapy
    BJOG, 114 (9), 1150-8
    PubMed 17655733
19. Vistad I, Fosså SD, Kristensen GB, Mykletun A, Dahl AA (2007)
    The sexual activity questionnaire: pychometric properties and normative data in a norwegian population sample
    J Womens Health (Larchmt), 16 (1), 139-48
    PubMed 17324105
20. Wang Y, Kristensen GB, Børresen-Dale AL, Helland A (2007)
    TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients
    Ann Oncol, 18 (5), 964-6
    PubMed 17488735
21. Wu Q, Lind GE, Aasheim HC, Micci F, Silins I, Tropé CG, Nesland JM, Lothe RA, Suo Z (2007)
    The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers
    Epigenetics, 2 (4), 237-43
    PubMed 18281782
22. Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z, Lind GE (2007)
    DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets
    Mol Cancer, 6, 45
    PubMed 17623056
23. Zhang MZ, Qiao YH, Nesland JM, Trope C, Kennedy A, Chen WT, Suo ZH (2007)
    Expression of seprase in effusions from patients with epithelial ovarian carcinoma
    Chin Med J (Engl), 120 (8), 663-8
    PubMed 17517181

Publications 2006

1. Aghmesheh M, Suo Z, Friedlander M, Nesland JM, Kaern J, Stewart M, Kconfab, Dorum A, Tucker KM, Buckley MF (2006)
   Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas
   Pathology, 38 (2), 145-51
   PubMed 16680901
2. Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H (2006)
   High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection
   BMC Clin Pharmacol, 6, 2
   PubMed 16412237
3. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006)
   Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
   PLoS Med, 3 (3), e47
   PubMed 16417408
4. Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, Kohn EC (2006)
   Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
   Clin Cancer Res, 12 (3 Pt 1), 791-9
   PubMed 16467090
5. Davidson B, Trope' CG, Wang TL, Shih IeM (2006)
   Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival
   Gynecol Oncol, 103 (3), 814-9
   PubMed 16844205
6. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, Risberg B (2006)
   NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
   Am J Clin Pathol, 125 (3), 451-8
   PubMed 16613351
7. Elloul S, Silins I, Tropé CG, Benshushan A, Davidson B, Reich R (2006)
   Expression of E-cadherin transcriptional regulators in ovarian carcinoma
   Virchows Arch, 449 (5), 520-8
   PubMed 17024425
8. Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R (2006)
   The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
   Gynecol Oncol, 103 (3), 831-40
   PubMed 16919315
9. Knopp S, Holm R, Bjørge T, Tropé C, Nesland JM (2006)
   Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases
   Histopathology, 49 (3), 311-2
   PubMed 16918980
10. Knopp S, Nesland JM, Tropé C, Holm R (2006)
    p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma
    Am J Clin Pathol, 126 (2), 266-76
    PubMed 16891203
11. Knudsen A, Monstad SE, Dørum A, Lønning PE, Salvesen HB, Drivsholm L, Aarseth JH, Vedeler CA (2006)
    Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique
    Cancer Immunol Immunother, 55 (10), 1280-4
    PubMed 16429314
12. Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, Skomedal H (2006)
    Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas
    J Clin Microbiol, 44 (4), 1310-7
    PubMed 16597856
13. Lyng H, Brøvig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, Oksefjell H, Sundfør K, Kristensen GB, Stokke T (2006)
    Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer
    BMC Genomics, 7, 268
    PubMed 17054779
14. Monstad SE, Storstein A, Dørum A, Knudsen A, Lønning PE, Salvesen HB, Aarseth JH, Vedeler CA (2006)
    Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique
    Clin Exp Immunol, 144 (1), 53-8
    PubMed 16542365
15. Oksefjell H, Sandstad B, Trope C (2006)
    Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival
    Eur J Gynaecol Oncol, 27 (3), 209-14
    PubMed 16800244
16. Paulsen T, Kaern J, Kjaerheim K, Haldorsen T, Tropé C (2006)
    Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer
    Gynecol Oncol, 102 (3), 447-52
    PubMed 16516277
17. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C (2006)
    Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
    Int J Gynecol Cancer, 16 Suppl 1, 11-7
    PubMed 16515561
18. Pradhan M, Abeler VM, Danielsen HE, Tropé CG, Risberg BA (2006)
    Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas
    Mod Pathol, 19 (9), 1227-35
    PubMed 16729014
19. Sert B, Abeler VM, Dørum A, Trope CG (2006)
    A new approach to treatment of early-stage cervical carcinoma: entire laparoscopic abdominal radical hysterectomy with bilateral pelvic lymphadenectomy without vaginal cuff closure--case reports
    Eur J Gynaecol Oncol, 27 (5), 513-8
    PubMed 17139990
20. Sert BM, Abeler VM (2006)
    Robotic-assisted laparoscopic radical hysterectomy (Piver type III) with pelvic node dissection--case report
    Eur J Gynaecol Oncol, 27 (5), 531-3
    PubMed 17139995
21. Tropé C, Kaern J (2006)
    Primary surgery for ovarian cancer
    Eur J Surg Oncol, 32 (8), 844-52
    PubMed 16677797
22. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MMO, Olivier M, Skomedal H, Hainaut P, Trope CG, Abeler VM, Nesland JM, Borresen-Dale AL, Helland A (2006)
    Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (vol 24, pg 21, 2004)
    Hum. Mutat., 27 (2), 209-210
23. Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM (2006)
    The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma
    Gynecol Oncol, 102 (1), 15-21
    PubMed 16499955
24. Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B (2006)
    The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
    Gynecol Oncol, 100 (3), 462-8
    PubMed 16216317

Publications 2005

1. Benetkiewicz M, Wang Y, Schaner M, Wang P, Mantripragada KK, Buckley PG, Kristensen G, Børresen-Dale AL, Dumanski JP (2005)
   High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas
   Genes Chromosomes Cancer, 42 (3), 228-37
   PubMed 15578687
2. Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, Yu A, Davidson B, Shih IeM (2005)
   Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
   Cancer Res, 65 (1), 331-7
   PubMed 15665311
3. Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IeM (2005)
   HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma
   Gynecol Oncol, 96 (1), 42-7
   PubMed 15589578
4. Davidson B, Xi Z, Klokk TI, Tropé CG, Dørum A, Scheistrøen M, Saatcioglu F (2005)
   Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
   Am J Clin Pathol, 123 (3), 360-8
   PubMed 15716231
5. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A et al. (2005)
   2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
   Ann Oncol, 16 Suppl 8, viii7-viii12
   PubMed 16239238
6. Dørum A, Blom GP, Ekerhovd E, Granberg S (2005)
   Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study
   Am J Obstet Gynecol, 192 (1), 48-54
   PubMed 15672002
7. Elfgren K, Rylander E, Rådberg T, Strander B, Strand A, Paajanen K, Sjöberg I, Ryd W, Silins I, Dillner J, Swedescreen Study Group (2005)
   Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence
   Am J Obstet Gynecol, 193 (3 Pt 1), 650-7
   PubMed 16150255
8. Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B (2005)
   Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma
   Cancer, 103 (8), 1631-43
   PubMed 15742334
9. Gryspeerdt S, Lefere P, Herman M, Deman R, Rutgeerts L, Ghillebert G, Baert F, Baekelandt M, Van Holsbeeck B (2005)
   CT colonography with fecal tagging after incomplete colonoscopy
   Eur Radiol, 15 (6), 1192-202
   PubMed 15702335
10. Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM, Suo Z (2005)
    The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas
    Gynecol Oncol, 99 (2), 278-86
    PubMed 16061279
11. Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, Tropé C (2005)
    Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
    Int J Gynecol Cancer, 15 (6), 1014-22
    PubMed 16343177
12. Kildal W, Risberg B, Abeler VM, Kristensen GB, Sudbø J, Nesland JM, Danielsen HE (2005)
    beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients
    Eur J Cancer, 41 (8), 1127-34
    PubMed 15911235
13. Knopp S, Bjørge T, Nesland JM, Tropé C, Holm R (2005)
    Cyclins D1, D3, E, and A in vulvar carcinoma patients
    Gynecol Oncol, 97 (3), 733-9
    PubMed 15894358
14. Knopp S, Holm R, Tropé C, Nesland JM (2005)
    Occult lymph node metastases in early stage vulvar carcinoma patients
    Gynecol Oncol, 99 (2), 383-7
    PubMed 16051338
15. Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A (2005)
    TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
    BMC Cancer, 5, 134
    PubMed 16229746
16. Lyngstadaas A, Ekanger R, Hagen B, Himmelmann A, Iversen OE, Iversen T, Nordal R, Norheim OF, Onsrud M, Tretli S, Tropé C (2005)
    [Primary treatment of ovarian cancer]
    Tidsskr Nor Laegeforen, 125 (3), 278-81
    PubMed 15702146
17. Marrannes J, Gryspeerdt S, Haspeslagh M, van Holsbeeck B, Baekelandt M, Lefere P (2005)
    Fibrolamellar hepatocellular carcinoma in a 65-year-old woman: CT features
    JBR-BTR, 88 (5), 237-40
    PubMed 16302333
18. Paulsen T, Kaern J, Kjaerheim K, Tropé C, Tretli S (2005)
    Symptoms and referral of women with epithelial ovarian tumors
    Int J Gynaecol Obstet, 88 (1), 31-7
    PubMed 15617702
19. Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B (2005)
    Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities
    Diagn Cytopathol, 33 (5), 332-7
    PubMed 16240397
20. Salvesen HB, Iversen OE, Tropé C (2005)
    [Molecular diagnostic techniques in gynaecologic cancer]
    Tidsskr Nor Laegeforen, 125 (22), 3120-3
    PubMed 16299569
21. Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Tropè CG, Kristensen GB, Nesland JM, Børresen-Dale AL (2005)
    Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
    Mol Cancer, 4, 26
    PubMed 16042759
22. Shih IeM, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, Davidson B, Wang TL (2005)
    Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
    Proc Natl Acad Sci U S A, 102 (39), 14004-9
    PubMed 16172393
23. Silins I, Ryd W, Strand A, Wadell G, Törnberg S, Hansson BG, Wang X, Arnheim L, Dahl V, Bremell D, Persson K, Dillner J, Rylander E (2005)
    Chlamydia trachomatis infection and persistence of human papillomavirus
    Int J Cancer, 116 (1), 110-5
    PubMed 15756673
24. Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B (2005)
    Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma
    Cancer, 103 (11), 2313-9
    PubMed 15844177
25. Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J et al. (2005)
    3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration
    Ann Oncol, 16 Suppl 8, viii36-viii38
    PubMed 16239235
26. Thigpen T, Stuart G, du Bois A, Friedlander M, Fujiwara K, Guastalla JP, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Poveda A, Provencher D, Stehman F, Vergote I, Gynecologic Cancer Intergroup, GOG, NCIC-CTG, AGO-OVAR, ANZGOG, JGOG, GINECO, SGCTG, MRC/NCRI et al. (2005)
    Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens
    Ann Oncol, 16 Suppl 8, viii13-viii19
    PubMed 16239232
27. Van de Putte G, Holm R, Lie AK, Baekelandt M, Kristensen GB (2005)
    Markers of apoptosis in stage IB squamous cervical carcinoma
    J Clin Pathol, 58 (6), 590-4
    PubMed 15917408
28. Van de Putte G, Lie AK, Vach W, Baekelandt M, Kristensen GB (2005)
    Risk grouping in stage IB squamous cell cervical carcinoma
    Gynecol Oncol, 99 (1), 106-12
    PubMed 16137752
29. Van de Putte G, Vach W (2005)
    Re: "P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma"
    Gynecol Oncol, 98 (2), 335-6
    PubMed 16039312
30. Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL (2005)
    PIK3CA mutations in advanced ovarian carcinomas
    Hum Mutat, 25 (3), 322
    PubMed 15712344
31. Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R (2005)
    Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
    Am J Clin Pathol, 124 (3), 392-401
    PubMed 16191507

Publications 2004

1. Aghmesheh M, Nesland JM, Kaern J, Dorum A, Edwards L, Byth K, Friedlander M, Jackson P, Tucker KM, Russell PJ (2004)
   No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers
   Gynecol Oncol, 95 (3), 430-6
   PubMed 15581943
2. Bjørge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, Langseth H, Nustad K, Tropé CG, Dørum A (2004)
   BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study
   Br J Cancer, 91 (10), 1829-34
   PubMed 15477862
3. Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC (2004)
   Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
   Cancer, 100 (10), 2139-47
   PubMed 15139056
4. Davidson B, Goldberg I, Tell L, Vigdorchik S, Baekelandt M, Berner A, Kristensen GB, Reich R, Kopolovic J (2004)
   The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions
   Clin Exp Metastasis, 21 (3), 191-9
   PubMed 15387369
5. Davidson B, Reich R, Lazarovici P, Flørenes VA, Risberg B, Nielsen S, Sert B, Bedrossian C (2004)
   Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma
   Lung Cancer, 44 (2), 159-65
   PubMed 15084380
6. Dueholm M, Rokkones E, Löfgren M, Härkki P, Arason G (2004)
   Nordic gynecologists' opinion on quality assessment registers
   Acta Obstet Gynecol Scand, 83 (6), 563-9
   PubMed 15144339
7. Ekstrøm PO, Bjørge T, Dørum A, Longva AS, Heintz KM, Warren DJ, Hansen S, Gislefoss RE, Hovig E (2004)
   Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis
   Anal Chem, 76 (15), 4406-9
   PubMed 15283579
8. Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Tropé CG, Reich R (2004)
   The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma
   Gynecol Oncol, 93 (2), 517-23
   PubMed 15099972
9. Jacobsen AF, Drolsum A, Klow NE, Dahl GF, Qvigstad E, Sandset PM (2004)
   Deep vein thrombosis after elective cesarean section
   Thromb Res, 113 (5), 283-8
   PubMed 15183039
10. Kildal W, Kaern J, Kraggerud SM, Abeler VM, Sudbø J, Tropè CG, Lothe RA, Danielsen HE (2004)
    Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables
    Cancer Genet Cytogenet, 155 (1), 25-32
    PubMed 15527899
11. Knopp S, Bjørge T, Nesland JM, Tropé C, Scheistrøen M, Holm R (2004)
    p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas
    Gynecol Oncol, 95 (1), 37-45
    PubMed 15385108
12. Kristensen G, Tropé C (2004)
    Endometrial cancer: the management of high-risk disease
    Curr Oncol Rep, 6 (6), 471-5
    PubMed 15485617
13. Langeland T, Rokkones E (2004)
    Pyoderma gangrenosum as a cause of spontaneous vulvovaginal ulceration
    Acta Obstet Gynecol Scand, 83 (12), 1220-1
    PubMed 15548161
14. Lyng H, Beigi M, Svendsrud DH, Brustugun OT, Stokke T, Kristensen GB, Sundfør K, Skjønsberg A, De Angelis PM (2004)
    Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix
    Int J Cancer, 111 (3), 358-66
    PubMed 15221962
15. Mebis J, De Raeve H, Baekelandt M, Tjalma WA, Vermorken JB (2004)
    Primary ovarian small cell carcinoma of the pulmonary type: a case report and review of the literature
    Eur J Gynaecol Oncol, 25 (2), 239-41
    PubMed 15032292
16. Micci F, Teixeira MR, Haugom L, Kristensen G, Abeler VM, Heim S (2004)
    Genomic aberrations in carcinomas of the uterine corpus
    Genes Chromosomes Cancer, 40 (3), 229-46
    PubMed 15139002
17. Silins I, Wang X, Tadesse A, Jansen KU, Schiller JT, Avall-Lundqvist E, Frankendal B, Dillner J (2004)
    A population-based study of cervical carcinoma and HPV infection in Latvia
    Gynecol Oncol, 93 (2), 484-92
    PubMed 15099967
18. Suo Z, Karbovo E, Trope CG, Metodiev K, Nesland JM (2004)
    Papillary serous carcinoma of the ovary: an ultrastructural and immunohistochemical study
    Ultrastruct Pathol, 28 (3), 141-7
    PubMed 15471427
19. Van de Putte G, Kristensen GB, Baekelandt M, Lie AK, Holm R (2004)
    E-cadherin and catenins in early squamous cervical carcinoma
    Gynecol Oncol, 94 (2), 521-7
    PubMed 15297198
20. Van de Putte G, Kristensen GB, Lie AK, Baekelandt M, Holm R (2004)
    Cyclins and proliferation markers in early squamous cervical carcinoma
    Gynecol Oncol, 92 (1), 40-6
    PubMed 14751136
21. Van de Putte GV, Holm R, Lie AK, Trope CG, Kristensen GB (2004)
    Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis (vol 89, pg 140, 2003)
    Gynecol. Oncol., 92 (2), 730
22. Van Mieghem IM, Gryspeerdt S, Baekelandt M, van Holsbeeck B, Lefere P, Haspeslagh M, Dalle I (2004)
    Papillary serous adenocarcinoma of the endometrium: CT-pathologic correlation
    AJR Am J Roentgenol, 182 (6), 1534-6
    PubMed 15150003
23. Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL, Kristensen GB (2004)
    TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
    Br J Cancer, 90 (3), 678-85
    PubMed 14760384
24. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A (2004)
    Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
    Hum Mutat, 24 (1), 21-34
    PubMed 15221786
25. Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland JM, Suo Z (2004)
    Prognostic significance of dysadherin expression in cervical squamous cell carcinoma
    Pathol Oncol Res, 10 (4), 212-8
    PubMed 15619642
26. Wu D, Suo Z, Kristensen GB, Li S, Troen G, Holm R, Nesland JM (2004)
    Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma
    Gynecol Oncol, 94 (2), 312-9
    PubMed 15297167
27. Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Tropé C, Saatcioglu F (2004)
    Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
    Gynecol Oncol, 94 (1), 80-5
    PubMed 15262123

Publications 2003

1. Alfsen GC, Reed W, Sandstad B, Kristensen GB, Abeler VM (2003)
   The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma
   Cancer, 98 (9), 1880-9
   PubMed 14584070
2. Baekelandt M (2003)
   The potential role of neoadjuvant chemotherapy in advanced ovarian cancer
   Int J Gynecol Cancer, 13 Suppl 2, 163-8
   PubMed 14656274
3. Benedetti-Panici P, Bermudez A, Blake P, Cardenas J, Chang TC, Chiara S, Di Paola G, Floquet A, Guthrie D, Kigawa J, Kumar L, Leborgne F, Lodge N, Poole C, Sardi J, Souhami L, Sundfor K, Symonds P, Tattersall M, Greggi S, Guthrie D, Parker V, Parmar MKB, Sardi J, Stewart LA et al. (2003)
   Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials
   Eur. J. Cancer, 39 (17), 2470-2486
4. Colombo N, du Bois A, Kristensen G, Ledermann J, Torri V, ICON4 Collaborators (2003)
   ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit - Reply
   Lancet, 362 (9392), 1334
5. Davidson B, Givant-Horwitz V, Lazarovici P, Risberg B, Nesland JM, Trope CG, Schaefer E, Reich R (2003)
   Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma
   Clin Exp Metastasis, 20 (7), 621-31
   PubMed 14669793
6. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R (2003)
   EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma
   Clin Exp Metastasis, 20 (2), 161-9
   PubMed 12705637
7. Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Trope' CG, Risberg B, Kopolovic J (2003)
   AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients
   Gynecol Oncol, 90 (2), 248-57
   PubMed 12893184
8. Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA (2003)
   Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
   Clin Cancer Res, 9 (6), 2248-59
   PubMed 12796393
9. Einhorn N, Tropé C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E (2003)
   A systematic overview of radiation therapy effects in uterine cancer (corpus uteri)
   Acta Oncol, 42 (5-6), 557-61
   PubMed 14596513
10. Einhorn N, Tropé C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E (2003)
    A systematic overview of radiation therapy effects in ovarian cancer
    Acta Oncol, 42 (5-6), 562-6
    PubMed 14596514
11. Einhorn N, Tropé C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E (2003)
    A systematic overview of radiation therapy effects in cervical cancer (cervix uteri)
    Acta Oncol, 42 (5-6), 546-56
    PubMed 14596512
12. Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Tropé CG, Reich R (2003)
    Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions
    Gynecol Oncol, 91 (1), 160-72
    PubMed 14529677
13. Givant-Horwitz V, Davidson B, van de Putte G, Dong HP, Goldberg I, Amir S, Kristensen GB, Reich R (2003)
    Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma
    Clin Exp Metastasis, 20 (7), 599-609
    PubMed 14669791
14. Hermans RH, Fischer DC, van der Putten HW, van de Putte G, Einzmann T, Vos MC, Kieback DG (2003)
    Adnexal masses in pregnancy
    Onkologie, 26 (2), 167-72
    PubMed 12771526
15. Kildal W, Kraggerud SM, Abeler VM, Heim S, Tropé CG, Kristensen GB, Risberg B, Lothe RA, Danielsen HE (2003)
    Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female
    Hum Pathol, 34 (9), 946-9
    PubMed 14562293
16. Kohn EC, Fidler IJ, Fishman D, Jaffe R, Liotta LA, Van Trappen P, Mills GB, Trope C (2003)
    Discussion: Metastasis and angiogenesis in epithelial ovarian cancer
    Gynecol. Oncol., 88 (1), S37-S42
17. Kristensen GB, Kildal W, Abeler VM, Kaern J, Vergote I, Tropé CG, Danielsen HE (2003)
    Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer
    Ann Oncol, 14 (10), 1494-500
    PubMed 14504048
18. Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E (2003)
    First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin
    Int J Gynecol Cancer, 13 Suppl 2, 172-7
    PubMed 14656276
19. Kristiansen M, Helland A, Kristensen GB, Olsen AO, Lønning PE, Børresen-Dale AL, Ørstavik KH (2003)
    X chromosome inactivation in cervical cancer patients
    Cancer Genet Cytogenet, 146 (1), 73-6
    PubMed 14499700
20. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C, ICON and AGO Collaborators (2003)
    Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
    Lancet, 361 (9375), 2099-106
    PubMed 12826431
21. Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B et al. (2003)
    Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer
    Int J Gynecol Cancer, 13 Suppl 2, 144-8
    PubMed 14656271
22. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO et al. (2003)
    Gene expression patterns in ovarian carcinomas
    Mol Biol Cell, 14 (11), 4376-86
    PubMed 12960427
23. Thorstensen L, Holm R, Lothe RA, Tropé C, Carvalho B, Sobrinho-Simoes M, Seruca R (2003)
    WNT-inducible signaling pathway protein 3, WISP-3, is mutated in microsatellite unstable gastrointestinal carcinomas but not in endometrial carcinomas
    Gastroenterology, 124 (1), 270-1
    PubMed 12512062
24. Tropé C, Kaern J, Saeter G, Gore M (2003)
    [Paclitaxel should be included in standard therapy of ovarian carcinoma]
    Tidsskr Nor Laegeforen, 123 (21), 3083-4
    PubMed 14618184
25. Van de Putte G, Holm R, Lie AK, Trope CG, Kristensen GB (2003)
    Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis (vol 89, pg 140, 2003)
    Gynecol. Oncol., 90 (1), 231
26. van de Putte G, Holm R, Lie AK, Tropé CG, Kristensen GB (2003)
    Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis
    Gynecol Oncol, 89 (1), 140-7
    PubMed 12694668

Publications 2002

1. Baekelandt M (2002)
   Hormonal treatment of endometrial carcinoma
   Expert Rev Anticancer Ther, 2 (1), 106-12
   PubMed 12113059
2. Baekelandt M (2002)
   Irofulven (MGI Pharma)
   Curr Opin Investig Drugs, 3 (10), 1517-26
   PubMed 12431030
3. Bjørge T, Abeler VM, Sundfør K, Tropé CG, Kaern J (2002)
   Gestational trophoblastic tumors in Norway, 1968-1997: patient characteristics, treatment, and prognosis
   Gynecol Oncol, 87 (1), 71-6
   PubMed 12468345
4. Bjørge T, Engeland A, Luostarinen T, Mork J, Gislefoss RE, Jellum E, Koskela P, Lehtinen M, Pukkala E, Thoresen SØ, Dillner J (2002)
   Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study
   Br J Cancer, 87 (1), 61-4
   PubMed 12085257
5. Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, Risberg B, Kopolovic J, Kristensen GB, Tropé CG, van de Putte G, Reich R (2002)
   Caveolin-1 expression in ovarian carcinoma is MDR1 independent
   Am J Clin Pathol, 117 (2), 225-34
   PubMed 11863219
6. Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, Tropé CG, Bryne M, Risberg B, van de Putte G, Goldberg I (2002)
   Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions
   Clin Exp Metastasis, 19 (2), 135-44
   PubMed 11964077
7. Gryspeerdt S, Lefere P, Dewyspelaere J, Baekelandt M, van Holsbeeck B (2002)
   Optimisation of colon cleansing prior to computed tomographic colonography
   JBR-BTR, 85 (6), 289-96
   PubMed 12553658
8. Kaern J, Baekelandt M, Tropé CG (2002)
   A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients
   Eur J Gynaecol Oncol, 23 (5), 383-9
   PubMed 12440808
9. Karbova E, Davidson B, Metodiev K, Tropé CG, Nesland JM (2002)
   Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma
   Int J Surg Pathol, 10 (3), 175-80
   PubMed 12232570
10. Marth C, Kisic J, Kaern J, Tropé C, Fodstad Ø (2002)
    Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis
    Cancer, 94 (3), 707-12
    PubMed 11857303
11. Monclair T, Abeler VM, Kaern J, Walaas L, Zeller B, Hilstrøm C (2002)
    Placental site trophoblastic tumor (PSTT) in mother and child: first report of PSTT in infancy
    Med Pediatr Oncol, 38 (3), 187-91; discussion 192
    PubMed 11836719
12. Scheistrøen M, Nesland JM, Tropé C (2002)
    Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977-1991
    Eur J Gynaecol Oncol, 23 (2), 93-103
    PubMed 12013120
13. Silins I, Avall-Lundqvist E, Tadesse A, Jansen KU, Stendahl U, Lenner P, Zumbach K, Pawlita M, Dillner J, Frankendal B (2002)
    Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients
    Gynecol Oncol, 85 (2), 333-8
    PubMed 11972397
14. Silins I, Tedeschi RM, Kallings I, Dillner J (2002)
    Clustering of seropositivities for sexually transmitted infections
    Sex Transm Dis, 29 (4), 207-11
    PubMed 11912461
15. Tropé C (2002)
    [Laparoscopic surgery in endometrial carcinoma]
    Tidsskr Nor Laegeforen, 122 (25), 2429
    PubMed 12448107
16. Tropé C (2002)
    [Mass screening against endometrial cancer?]
    Tidsskr Nor Laegeforen, 122 (18), 1767
    PubMed 12362684

Publications 2001

1. Alfsen GC, Kristensen GB, Skovlund E, Pettersen EO, Abeler VM (2001)
   Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix
   Cancer, 92 (9), 2471-83
   PubMed 11745305
2. Baekelandt M, Lehne G, Tropé CG, Szántó I, Pfeiffer P, Gustavssson B, Kristensen GB (2001)
   Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer
   J Clin Oncol, 19 (12), 2983-93
   PubMed 11408493
3. Baay MF, Tjalma WA, Weyler J, Pattyn GG, Lambrechts HA, Goovaerts G, Baekelandt M, Buytaert P, Van Marck EA, Lardon F, Vermorken JB (2001)
   Prevalence of human papillomavirus in elderly women with cervical cancer
   Gynecol Obstet Invest, 52 (4), 248-51
   PubMed 11729338
4. Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW, Hanjani P, Kristensen G, Malfetano JH, Beckman RA, Ross GA, Lane SR, DeWitte MH, Fields SZ (2001)
   Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer
   J Clin Oncol, 19 (19), 3967-75
   PubMed 11579118
5. Dai H, Holm R, Kristensen GB, Abeler VM, Børresen-Dale AL, Helland A (2001)
   Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas
   Anal Cell Pathol, 23 (2), 45-9
   PubMed 11904459
6. Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz V, Bryne M, Risberg B, Kristensen GB, Tropé CG, Kopolovic J, Reich R (2001)
   Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
   Am J Clin Pathol, 115 (4), 517-24
   PubMed 11293899
7. Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R (2001)
   Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
   Clin Cancer Res, 7 (11), 3457-64
   PubMed 11705863
8. Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Trope CG, Bryne M, Kopolovic J, Nesland JM (2001)
   Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
   Eur J Cancer, 37 (16), 2040-9
   PubMed 11597382
9. Davidson B, Risberg B, Berner A, Nesland JM, Tropé CG, Kristensen GB, Bryne M, Goscinski M, van de Putte G, Flørenes VA (2001)
   Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
   Gynecol Oncol, 83 (2), 249-56
   PubMed 11606079
10. Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Tropé CG, Kristensen GB, Bryne M, Reich R (2001)
    Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome
    Am J Surg Pathol, 25 (12), 1493-500
    PubMed 11717538
11. Jensen N, Kristensen G (2001)
    Frequency of nightly wetting and the efficiency of alarm treatment of nocturnal enuresis
    Scand J Urol Nephrol, 35 (5), 357-63
    PubMed 11771861
12. Kristensen GB, Johannesen H, Aamand J (2001)
    Mineralization of aged atrazine and mecoprop in soil and aquifer chalk
    Chemosphere, 45 (6-7), 927-34
    PubMed 11695615
13. Kristensen GB, Sørensen SR, Aamand J (2001)
    Mineralization of 2,4-D, mecoprop, isoproturon and terbuthylazine in a chalk aquifer
    Pest Manag Sci, 57 (6), 531-6
    PubMed 11407030
14. Lyng H, Sundfor K, Rofstad EK (2001)
    Serial changes in tumor oxygenation during the early phase of radiation therapy in cervical cancer - Are we quantitating hypoxia change? Response
    Int. J. Radiat. Oncol. Biol. Phys., 49 (1), 285-289
15. Lyng H, Vorren AO, Sundfør K, Taksdal I, Lien HH, Kaalhus O, Rofstad EK (2001)
    Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging
    J Magn Reson Imaging, 14 (6), 750-6
    PubMed 11747032
16. Lyng H, Vorren AO, Sundfør K, Taksdal I, Lien HH, Kaalhus O, Rofstad EK (2001)
    Intra- and intertumor heterogeneity in blood perfusion of human cervical cancer before treatment and after radiotherapy
    Int J Cancer, 96 (3), 182-90
    PubMed 11410887
17. Makar AP, Scheistroen M, van den Weyngaert D, Tropé CG (2001)
    Surgical management of stage I and II vulvar cancer: the role of the sentinel node biopsy. Review of literature
    Int J Gynecol Cancer, 11 (4), 255-62
    PubMed 11520362
18. Makar AP, Tropé C (2001)
    Fertility preservation in gynecologic cancer
    Acta Obstet Gynecol Scand, 80 (9), 794-802
    PubMed 11531628
19. Paulsen T, Kjaerheim K, Kaern J, Norstein J, Onsrud M (2001)
    [Examination, treatment and follow-up of ovarian cancer in Norway]
    Tidsskr Nor Laegeforen, 121 (23), 2696-700
    PubMed 11699376
20. Silins I, Finnberg N, Ståhl A, Högberg J, Stenius U (2001)
    Reduced ATM kinase activity and an attenuated p53 response to DNA damage in carcinogen-induced preneoplastic hepatic lesions in the rat
    Carcinogenesis, 22 (12), 2023-31
    PubMed 11751435
21. Tropé C, Kristensen G, Kisic J, Kaern J (2001)
    Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer
    Eur J Gynaecol Oncol, 22 (3), 223-7
    PubMed 11501778
22. Tropé C, Kristensen GB, Abeler VM (2001)
    Clear-cell and papillary serous cancer: treatment options
    Best Pract Res Clin Obstet Gynaecol, 15 (3), 433-46
    PubMed 11476564
23. Tropé C, Scheistrøen M, Makar AP (2001)
    [Fertility preservation in gynecologic cancer]
    Tidsskr Nor Laegeforen, 121 (10), 1234-9
    PubMed 11402751
24. Tropé C, Scheistrøen M, Aas M, Abeler V, Lie K, Makar A (2001)
    [Surgery and sentinel node examination in early vulvar cancer]
    Tidsskr Nor Laegeforen, 121 (23), 2723-7
    PubMed 11699381
25. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J, Verrelst H, Sjövall K, Timmerman D, Vandewalle J, Van Gramberen M, Tropé CG (2001)
    Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
    Lancet, 357 (9251), 176-82
    PubMed 11213094

Publications 2000

1. Abeler VM, Tropé CG (2000)
   [Early stage ovarian carcinoma--diagnosis and treatment]
   Tidsskr Nor Laegeforen, 120 (4), 476-8
   PubMed 10833940
2. Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM (2000)
   Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990
   Cancer, 89 (6), 1291-9
   PubMed 11002225
3. Baekelandt M, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
   Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer
   J Clin Oncol, 18 (22), 3775-81
   PubMed 11078490
4. Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Tropé CG, Abeler VM (2000)
   Carcinoma of the fallopian tube
   Cancer, 89 (10), 2076-84
   PubMed 11066048
5. Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
   P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
   Anticancer Res, 20 (2B), 1061-7
   PubMed 10810398
6. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Lück HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT et al. (2000)
   [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]
   Gynecol Obstet Fertil, 28 (7-8), 576-83
   PubMed 10996969
7. Berner HS, Davidson B, Berner A, Risberg B, Kristensen GB, Trope CG, Van de Putte G, Nesland JM (2000)
   Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications
   Clin Exp Metastasis, 18 (2), 197-202
   PubMed 11235996
8. Bjørge T, Dørum A, Tropé CG (2000)
   [Screening for ovarian cancer]
   Tidsskr Nor Laegeforen, 120 (12), 1444-8
   PubMed 10851943
9. Bye A, Tropé C, Loge JH, Hjermstad M, Kaasa S (2000)
   Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy--evaluation of long-term effects of diagnosis and treatment
   Acta Oncol, 39 (2), 173-80
   PubMed 10859007
10. Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Tropè CG, Kristensen GB, Bryne M, Ann Florenes V (2000)
    E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
    J Pathol, 192 (4), 460-9
    PubMed 11113863
11. Davidson B, Berner A, Nesland JM, Risberg B, Kristensen GB, Tropé CG, Bryne M (2000)
    Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
    Hum Pathol, 31 (9), 1081-7
    PubMed 11014575
12. Helland A, Kraggerud SM, Kristensen GB, Holm R, Abeler VM, Huebner K, Borresen-Dale AL, Lothe RA (2000)
    Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival
    Int J Cancer, 88 (2), 217-22
    PubMed 11004671
13. Kraggerud SM, Szymanska J, Abeler VM, Kaern J, Eknaes M, Heim S, Teixeira MR, Tropé CG, Peltomäki P, Lothe RA (2000)
    DNA copy number changes in malignant ovarian germ cell tumors
    Cancer Res, 60 (11), 3025-30
    PubMed 10850452
14. Lyng H, Sundfør K, Rofstad EK (2000)
    Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis
    Int J Radiat Oncol Biol Phys, 46 (4), 935-46
    PubMed 10705016
15. Lyng H, Sundfør K, Tropé C, Rofstad EK (2000)
    Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy
    Clin Cancer Res, 6 (3), 1104-12
    PubMed 10741740
16. Makar AP, Kisic J, Tropé CG (2000)
    Controversies in surgical management of advanced ovarian cancer (stage III-IV)
    Eur J Gynaecol Oncol, 21 (5), 449-60
    PubMed 11198031
17. Mertens H, Van Holsbeeck B, Gryspeerdt S, Gellens P, Baekelandt M, Lefere P (2000)
    Percutaneous treatment of acute multiple limb ischemia
    JBR-BTR, 83 (5), 238-42
    PubMed 11201538
18. Paulsen T, Marth C, Kaern J, Nustad K, Kristensen GB, Tropé C (2000)
    Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
    Gynecol Oncol, 76 (3), 326-30
    PubMed 10684705
19. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B et al. (2000)
    Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
    J Natl Cancer Inst, 92 (9), 699-708
    PubMed 10793106
20. Rofstad EK, Sundfør K, Lyng H, Tropé CG (2000)
    Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis
    Br J Cancer, 83 (3), 354-9
    PubMed 10917551
21. Silins I, Kallings I, Dillner J (2000)
    Correlates of the spread of human papillomavirus infection
    Cancer Epidemiol Biomarkers Prev, 9 (9), 953-9
    PubMed 11008914
22. Sundfør K, Lyng H, Tropé CG, Rofstad EK (2000)
    Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization
    Radiother Oncol, 54 (2), 101-7
    PubMed 10699471
23. Tedeschi R, Caggiari L, Silins I, Kallings I, Andersson-Ellström A, De Paoli P, Dillner J (2000)
    Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women
    Int J Cancer, 87 (2), 232-5
    PubMed 10861480
24. Tropé C (2000)
    [Ovarian cancer screening of high risk groups]
    Tidsskr Nor Laegeforen, 120 (18), 2191
    PubMed 11006746
25. Tropé C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, Onsrud M, Pettersen E, Rosenberg P, Sandvei R, Sundfor K, Vergote I (2000)
    Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
    Ann Oncol, 11 (3), 281-8
    PubMed 10811493
26. Tropé C, Marth C, Kaern J (2000)
    Tamoxifen in the treatment of recurrent ovarian carcinoma
    Eur J Cancer, 36 Suppl 4, S59-61
    PubMed 11056321
27. Tropé C, Paulsen T, Baekelandt M, Makar A (2000)
    [Controversies in surgical treatment of advanced ovarian cancer]
    Tidsskr Nor Laegeforen, 120 (7), 824-30
    PubMed 10806907
28. Tropé CG, Abeler V, Baekelandt M, Kaern J (2000)
    [DNA ploidy in epithelial ovarian cancer--an independent prognostic factor]
    Tidsskr Nor Laegeforen, 120 (1), 43-9
    PubMed 10815478
29. Tropé CG, Baekelandt M, Bjørge T, Abeler V, Kaern J (2000)
    [Borderline tumors of the ovary]
    Tidsskr Nor Laegeforen, 120 (23), 2764-70
    PubMed 11107921
30. Tropé CG, Kisic J, Vergote I (2000)
    Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etoposide
    Eur J Gynaecol Oncol, 21 (3), 255-9
    PubMed 10949388
31. Tropé CG, Kristensen G, Makar A (2000)
    Surgery for borderline tumor of the ovary
    Semin Surg Oncol, 19 (1), 69-75
    PubMed 10883027
32. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB (2000)
    Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup
    J Natl Cancer Inst, 92 (18), 1534-5
    PubMed 10995813
33. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, Mueller-Klieser W (2000)
    High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers
    Cancer Res, 60 (4), 916-21
    PubMed 10706105
34. Aanderud L, Thorsen E, Brattebø G, Forland M, Kristensen G (2000)
    [Hyperbaric oxygen treatment for radiation reactions]
    Tidsskr Nor Laegeforen, 120 (9), 1020-2
    PubMed 10833959